Breaking Down PhiChem Corporation Financial Health: Key Insights for Investors

PhiChem Corporation's mid‑2025 numbers paint a nuanced picture for investors: operating revenue in H1 2025 reached 1.462 billion yuan (up 3.80% year‑on‑year) with TTM revenue as of 30 Sept 2025 at 3.09 billion yuan (+6.48% YoY), supported by a workforce of 2,104 (revenue per employee ~1.47 million yuan) and 2024 annual revenue of 2.92 billion yuan (+6.92%) driven by nearly 30% YoY growth in wet electronic chemicals; profitability surged with H1 2025 net profit attributable to shareholders at 217 million yuan (+80.45% YoY), a net profit margin of 14.83% (up 6.30 ppt), TTM net income of 331.61 million yuan (EPS 0.61 yuan), ROE 7.45%, operating margin 14.13% and gross margin 36.26%, while balance‑sheet and valuation metrics show a moderate capital structure (gearing 27.41%), market capitalization of 12.31 billion yuan as of 20 Nov 2025 (up 57.37% YoY), EV/Revenue 3.60, EV/EBITDA 17.46, P/B 2.51, P/S 3.79 and TTM P/E 35.38 (forward P/E 34.56); liquidity signals are strong with a cash flow margin of 931.40% and OCF up 6.48% YoY (ROA 3.37%), while shareholder dilution reduced major holders' stakes from 23.92% to 22.59% after convertible bond conversions and buybacks, and strategic growth levers include an MOU to acquire China LCD material assets from JNC, expansion into liquid crystal and advanced‑packaging EMC epoxy markets, targeted R&D and patents, even as the firm faces regulatory, competitive, raw‑material and cyclical demand risks.

PhiChem Corporation (300398.SZ) - Revenue Analysis

PhiChem Corporation's top-line trajectory through 2024-2025 shows steady expansion driven largely by semiconductor-materials demand, with wet electronic chemicals as a standout growth driver.

• Operating revenue (1H2025): 1.462 billion yuan - +3.80% vs. 1H2024
• TTM revenue (as of 2025-09-30): 3.09 billion yuan - +6.48% YoY
• Annual revenue (2024): 2.92 billion yuan - +6.92% vs. 2023
• Revenue per employee: ~1.47 million yuan (2,104 employees)
• Market capitalization (2025-11-20): 12.31 billion yuan - +57.37% YoY

Key driver detail:

• Semiconductor materials demand - particularly wet electronic chemicals - grew nearly 30% YoY in 2024, materially contributing to revenue growth.

For investor-focused context and ownership dynamics tied to this revenue profile, see: Exploring PhiChem Corporation Investor Profile: Who's Buying and Why?

PhiChem Corporation (300398.SZ) - Profitability Metrics

• H1 2025 net profit attributable to shareholders: 217.00 million yuan (↑80.45% YoY)
• Net profit margin (H1 2025): 14.83% (↑6.30 percentage points YoY)
• TTM net income (as of 2025-09-30): 331.61 million yuan; EPS (TTM): 0.61 yuan
• Return on equity (ROE): 7.45%
• Operating margin: 14.13%
• Gross margin: 36.26%

PhiChem Corporation (300398.SZ) - Debt vs. Equity Structure

• Gearing ratio: 27.41% - indicates a moderate level of debt relative to equity, leaving room for additional borrowing if needed while maintaining financial stability.
• Enterprise Value / Revenue (EV/Rev): 3.60 - investors are paying 3.60 yuan for each yuan of PhiChem's revenue, a reflection of growth expectations and sector positioning.
• Enterprise Value / EBITDA (EV/EBITDA): 17.46 - suggests a relatively premium valuation versus operating cash profits, implying market optimism or limited near-term EBITDA expansion.

• Shareholder composition: the drop from 23.92% to 22.59% in May 2025 reflects dilution from convertible bond conversions and the countervailing effects of buybacks - net change: -1.33%.
• Balance-sheet flexibility: with gearing at 27.41%, PhiChem can service current debt levels comfortably but a high EV/EBITDA (17.46) suggests the market expects sustained earnings or strategic assets justifying the premium.
• Valuation context: P/B of 2.51 and P/S of 3.79 indicate that equity and sales are priced above historical book and top-line baselines, signaling investor willingness to pay for anticipated growth or margin improvement.

PhiChem Corporation (300398.SZ) Liquidity and Solvency

• Cash flow margin: 931.40% - unusually high, indicating operating cash inflows far exceed reported sales in the period measured.
• Operating cash flow (OCF) growth: +6.48% year-over-year - steady improvement in cash generation from core operations.
• Return on assets (ROA): 3.37% - positive return reflecting reasonable asset efficiency in generating profit.
• Gearing ratio: 27.41% - suggests conservative leverage and limited reliance on debt financing.
• Enterprise value / EBITDA (EV/EBITDA): 17.46 - market valuation multiple showing how the market prices operating earnings before non-cash and financing items.
• Current ratio and quick ratio: not specified in available data; high cash flow margin supports an inference of adequate short-term liquidity.
• Debt-to-equity ratio: not specified; gearing ratio provides a proxy indicating modest leverage.

• Implications for investors: high cash flow margin combined with OCF growth implies strong internal funding capacity; a moderate ROA and conservative gearing reduce solvency risk; EV/EBITDA near 17.5 signals the market expects continued earnings strength or growth.
• Data gaps to monitor: obtain current and quick ratios and explicit debt-to-equity figures to fully assess short-term liquidity and capital structure resilience.

PhiChem Corporation (300398.SZ) - Valuation Analysis

Key valuation metrics for PhiChem Corporation (300398.SZ) provide a snapshot of how the market prices the company today relative to earnings, book value, revenue and cash-flow proxies. Below are the primary ratios investors frequently use when assessing valuation and relative attractiveness.

• Trailing twelve months (TTM) P/E: 35.38 - market values current earnings at 35.38×.
• Forward P/E: 34.56 - implies modest expected earnings growth priced in by investors.
• Price-to-Book (P/B): 2.51 - market values equity at 2.51× book value.
• Price-to-Sales (P/S): 3.79 - investors pay 3.79 yuan per yuan of revenue.
• Enterprise Value / Revenue (EV/Rev): 3.60 - overall firm valuation relative to revenue.
• Enterprise Value / EBITDA (EV/EBITDA): 17.46 - valuation versus cash-operating profitability.

Interpretation pointers investors should weigh:

• High P/E and EV/EBITDA suggest the market expects sustained margin expansion or above-market growth; verify guidance and R&D/product pipeline supporting that view.
• Forward P/E modestly below TTM P/E-market anticipates some earnings improvement but not dramatic re-rating.
• P/B of 2.51 indicates equity is priced above net assets-compare to sector peers to gauge premium justified by intangibles or superior returns on equity.
• P/S and EV/Rev in the ~3.6-3.8 range imply revenue is valued with a healthy multiple; check revenue growth rates and gross margin trends to validate.

For further context on the company's strategic direction and non-financial drivers that can affect valuation, see: Mission Statement, Vision, & Core Values (2026) of PhiChem Corporation.

PhiChem Corporation (300398.SZ) - Risk Factors

• Regulatory and environmental compliance: operating in the specialty chemicals sector in China and exporting to regulated markets exposes PhiChem to evolving environmental and chemical-safety rules that can raise capital expenditure, compliance costs, or restrict product sales.
• Competitive pressure: competition from domestic peers and global players (e.g., Huntsman, Hexion) can compress margins and erode market share, particularly in specialty/resin segments.
• Input-cost and FX volatility: exposure to raw-material price swings (petrochemical feedstocks, specialty intermediates) and foreign-exchange moves can materially affect gross margins and reported earnings.
• Demand cyclicality and supply-chain risk: industrial end-market cyclicality (coatings, adhesives, composites) and potential logistics or supplier disruptions can cause revenue volatility and production interruptions.
• Financial leverage and valuation sensitivity: a reported debt-to-equity ratio of 27.41% indicates moderate leverage; market valuation metrics such as an enterprise-value to EBITDA (EV/EBITDA) of 17.46 reflect investor expectations that could reverse under adverse conditions.

• Practical indicators investors should monitor: quarterly EBITDA trends vs. consensus, working-capital days, capex for environmental upgrades, feedstock cost pass-through to customers, RMB exchange-rate moves, and order-book trends in coatings/composites end markets.
• Corporate responses that can mitigate risk: diversification of feedstock suppliers, hedging FX/raw-material exposure, proactive environmental capex planning, and targeted product differentiation to defend margins.

PhiChem Corporation (300398.SZ) - Growth Opportunities

PhiChem Corporation (300398.SZ) is positioning to leverage structural industry shifts and internal capability upgrades to capture higher-margin segments across liquid crystal materials, epoxy systems for advanced packaging, and composite materials for electronics and renewables.

• Strategic M&A and asset acquisition: signed an MoU with JNC to acquire LCD material assets in China to consolidate supply, scale manufacturing and improve gross margins through vertical integration.
• Portfolio expansion: broadening product mix into high-growth end markets (advanced displays, EV/renewable composites, semiconductor advanced packaging) to diversify revenue streams and reduce cyclicality.
• R&D and innovation: accelerating independent innovation via industry-academia-research collaborations, building national-level R&D platforms, and recruiting international technical talent to shorten new-product development cycles.
• Upstream-to-high-value migration: transitioning EMC epoxy encapsulants from mid/low-end applications to higher-margin advanced packaging (fan-out WLP, SiP, 3D-IC) to capture premium pricing.
• Patent-backed differentiation: investing in epoxy formulations and application tech with multiple patents focused on improved thermal, mechanical and dielectric performance for high-reliability electronics.
• LCD market consolidation: expanding presence in LCD materials in China to improve bargaining power, secure feedstock channels and accelerate cross-selling with existing specialty polymer businesses.

Key execution levers to monitor:

• Integration timeline and synergies realized from the JNC asset acquisition (capex, workforce, supply contracts).
• R&D conversion: patent-to-revenue ratio and time-to-market for new epoxy/LCD formulations.
• Customer diversification in advanced packaging and renewables-percent of sales to top 10 customers and length of supply contracts.
• Margin expansion in EMC products as sales mix shifts to high-end applications.

Market and investor-read signals include quarterly revenue mix reports, capex disclosures for new capacity, patent filings, and partnership announcements. For further investor context and ownership dynamics, see: Exploring PhiChem Corporation Investor Profile: Who's Buying and Why?